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Abstract
Background: The mechanism by which vitrectomy improves macular edema in patients with branch retinal vein 
occlusion remains unclear, although intraocular levels of vascular endothelial growth factor have been suggested to 
influence the visual prognosis and macular edema.
Methods: A series of 54 consecutive patients (54 eyes) with branch retinal vein occlusion was studied prospectively. All 
patients underwent pars plana vitrectomy for treatment of macular edema. Best corrected visual acuity and retinal 
thickness (examined by optical coherence tomography) were assessed before and after surgery. The level of vascular 
endothelial growth factor in vitreous fluid harvested at operation was determined. Patients were followed for at least 6 
months postoperatively.
Results: Both the visual acuity and the retinal thickness showed significant improvement at 6 months postoperatively 
(P = 0.0002 and P < 0.0001, respectively). The vitreous level of vascular endothelial growth factor was significantly 
higher in patients who showed less improvement of visual acuity compared with those who had a better visual 
prognosis (p = 0.0135). In contrast, a high vitreous level of vascular endothelial growth factor was associated with 
greater improvement of macular edema (p = 0.0064).
Conclusions: These results suggest that the vitreous level of vascular endothelial growth factor might influence the 
visual prognosis and the response of macular edema to vitrectomy in patients with branch retinal vein occlusion.
Background
Branch retinal vein occlusion (BRVO) is a common reti-
nal vascular disease that often causes macular edema,
which is the main reason for visual impairment in these
patients[1,2]. We have been investigating various factors
t ha t might be in volved in t he pa thogenesis of macular
edema associated with BRVO. We recently reported that
the vitreous level of vascular endothelial growth factor
( V E G F )  i s  e l e v a t e d  i n  B R V O  p a t i e n t s  w i t h  m a c u l a r
edema, and that vitreous VEGF levels are correlated with
the non-perfused area of the retina and with the severity
of macular edema[3,4]. VEGF directly increases vascular
permeability[5], and VEGF expression by retinal glial
cells is upregulated due to hypoxia[6]. Accordingly, VEGF
may contribute to the occurrence of macular edema in
patients with BRVO, and a decrease of VEGF production
may be related to the improvement of macular edema in
BRVO patients who undergo pars plana vitrectomy
(PPV).
W e recently reported that higher VEGF levels in the
vitreous fluid were associated with more marked
improvement of macular edema after PPV in patients
with BRVO[7]. However, the relations between VEGF, the
visual prognosis, and the improvement of macular edema
after PPV need to be investigated in more detail. In the
present study, we evaluated the outcome of PPV for mac-
ular edema in patients with BRVO and examined the rela-
tions between VEGF in vitreous fluid, the final best
corrected visual acuity, and the response of macular
edema to PPV.
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Methods
Subjects
The subjects all underwent PPV at Tokyo Women's Med-
ical University Hospital or Eguchi Eye Hospital and undi-
luted vitreous fluid samples were harvested at the start of
surgery. Written informed consent was obtained from
each subject after an explanation was given about the
purpose and potential adverse effects of the procedure.
This study was performed in accordance with the Hel-
sinki Declaration of 1975 (1983 revision). The institu-
t i o n a l  r e v i e w  b o a r d s  o f  T o k y o  W o m e n ' s  M e d i c a l
University and Eguchi Eye Hospital both approved the
protocol for collection and testing of vitreous fluid. Con-
secutive patients presenting with BRVO between June
2005 and November 2008 were screened according to the
following criteria and 56 patients were enrolled. The indi-
cations for pars plana vitrectomy were: (1) clinically
detectable diffuse macular edema or cystoid macular
edema persisting for more than 3 months, (2) best-cor-
rected visual acuity worse than 20/40, and (3) macular
edema that persisted after retinal photocoagulation. Sig-
nificant macular edema was defined as retinal thickening
that covered at least one optic disc area and involved the
fovea[8]. The exclusion criteria for this study were (1)
ocular surgery within the previous 6 months, (2) diabetic
retinopathy, (3) iris rubeosis, (4) a history of ocular
inflammation or vitreoretinal disease, and (5) the reason
being previous ocular or vitreous injection of anti-VEGF
agent. Patients with iris rubeosis were excluded because
high cytokine levels have been reported in this disease[9]
and because its pathology may differ from that of macular
edema. Twenty-nine of the 54 patients underwent both
PPV and cataract surgery. During the 6-month postoper-
ative follow-up period after surgery, cataract extraction
was not performed in the other 25 patients who did not
have cataracts at baseline and additional scatter laser
photocoagulation was also not done.
Ocular investigations
Best-corrected visual acuity was measured before and
after PPV in decimal units and the data were converted to
the logarithm of the minimum angle of resolution (log
MAR) scale. Biomicroscopic examination was performed
with a fundus contact lens. Fundus findings were con-
firmed preoperatively by standardized fundus color pho-
tography and fluorescein angiography, which was
performed with a Topcon TRC-50EX fundus camera, an
image-net system (Tokyo Optical Co. Ltd., Japan), and a
preset lens with a slit-lamp.
A masked grader independently assessed ischemic reti-
nal vascular occlusion on fluorescein angiograms. The
ischemic region of the retina was measured with the pub-
lic domain Scion Image program, as reported previ-
ously[3,4,10]. In brief, the disc area was outlined on a
digital fundus photograph using a cursor and then was
measured. Next, the non-perfused area was outlined and
sites of retinal photocoagulation were excluded when cal-
culating the non-perfused area. Finally, the non-perfused
area was divided by the disc area as an index of retinal
ischemia.
Optical coherence tomography (OCT) (Zeiss-Hum-
phrey Ophthalmic Systems, Dublin, California, USA) was
performed in each subject within 1 week before surgery.
The fundi were scanned with the beam focused on hori-
zontal and vertical planes that crossed the central fovea,
which was located on the fundus photograph and by the
patient fixing on the central landmark during OCT. (All
subjects were able to maintain fixation.) Cross-sectional
images were collected by a single experienced examiner,
who continued each study until reproducible scans were
obtained. The thickness of the central fovea was defined
as the distance between the inner limiting membrane and
the retinal pigment epithelium (including any serous reti-
nal detachment), while the thickness of the neurosensory
retina was defined as the distance between the inner and
outer neurosensory retinal surfaces[11]. The severity of
macular edema was determined from the measured reti-
nal thickness and all measurements were obtained auto-
matically by computer analysis.
PPV and measurement of VEGF
Under local anaesthesia, all patients underwent standard
three-port PPV. All epiretinal material, the residual cor-
tex, and the posterior hyaloid were removed from the ret-
ina around the macula as completely as possible with the
assistance of triamcinolone acetonide, which was injected
into the eyeball at the minimum amount required and
then was removed as thoroughly as possible at the end of
surgery, because it can influence cystoid macular edema.
Scatter laser photocoagulation was also applied intraop-
eratively to the ischemic region of the retina in 24 eyes
(mean: 237 shots; range: 57 to 350 shots). Peeling of the
internal limiting membrane was not performed. All
patients were followed for at least 6 months postopera-
tively.
Samples of undiluted vitreous fluid (300-500 μl) were
collected into sterile tubes at the time of surgery and were
rapidly frozen at - 80°C for storage until VEGF was mea-
sured by an enzyme-linked immunosorbent assay using a
kit for human VEGF (R&D Systems, Minneapolis, MN,
USA)[3,4,10]. This assay detected two of the four iso-
forms of VEGF (VEGF121 and VEGF165). The minimum
detectable concentration of VEGF was 15.6 pg/ml (intra-
assay coefficient of variation: 5.4%; inter-assay coefficient:
6.8%), so the VEGF level in vitreous fluid samples was
within the detection range of the assay.Noma et al. BMC Ophthalmology 2010, 10:11
http://www.biomedcentral.com/1471-2415/10/11
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Statistical analysis
Analyses were performed with SAS System 9.1 software
(SAS Institute Inc., Cary, North Carolina, USA). Data are
presented as frequencies or as the mean ± SD. The paired
t-test was used to compare the retinal thickness and the
best-corrected visual acuity between the preoperative
values and those obtained 6 months after surgery. To
investigate the relation between each of the factors
assessed and macular edema, Spearman's rank-order cor-
relation coefficients were calculated. To identify factors
with an influence on the visual prognosis, multiple linear
regression analysis was performed, with the effects of
profile, linearity, interaction, and collinearity on the mul-
tiple linear models being examined by regression diag-
nostic analysis. In all analysis, a two-tailed P value of less
than 0.05 was taken to indicate statistical significance.
Results
Clinical profile
Of the 56 patients who were enrolled, 2 patients were lost
to follow-up because of transfer to another hospital for
personal reasons. The remaining 54 patients included 21
men and 33 women. Their mean age was 64.6 ± 10.0 years
(range: 40-87 years), and the mean duration of BRVO
before surgery was 4.5 ± 2.1 months (range: 3-10
months). Preoperative photocoagulation was done in 26
eyes (mean: 320 shots; range: 46 to 932). Retinal photoco-
agulation was done within 2.3 ± 1.5 months (range: 1 to 5
months) before surgery. None of the subjects received
treatment with anti-VEGF agents or triamcinolone ace-
tonide prior to surgery.
Visual acuity and foveal thickness after PPV
At the initial examination, the mean best-corrected visual
acuity was log MAR 0.84 ± 0.40, and it improved signifi-
cantly to log MAR 0.54 ± 0.39 by 6 months after PPV (P =
0.0002). Four patients (7%) showed deterioration of their
visual acuity, including two who had persistent macular
edema after surgery and two with macular atrophy. The
initial mean foveal thickness was 554. ± 182. μm and it
decreased significantly to 308. ± 130. μm by 6 months
after PPV (p < 0.0001). During PPV, a peripheral retinal
tear occurred in three eyes, but these tears were success-
fully managed by endolaser photocoagulation and sulfur
hexafluoride gas tamponade. Postoperatively, neovascu-
lar glaucoma was not detected in any of the patients after
follow up for six months.
Foveal thickness and the vitreous level of VEGF
The percent change of macular edema (%ΔME) was cal-
culated as follows:
where MEpr and MEpo correspond to the foveal thick-
ness before vitrectomy and 6 months after surgery,
respectively. There was a significant positive correlation
between the vitreous level of VEGF and %ΔME, with
VEGF levels being significantly higher in patients who
showed more marked improvement of macular edema
after PPV (r = 0.3666, p = 0.0064, Figure 1).
Visual acuity and the vitreous level of VEGF
The improvement of best-corrected visual acuity was cal-
culated by subtracting the postoperative visual acuity
from the preoperative acuity. There was a significant neg-
ative correlation between the vitreous level of VEGF and
the improvement of visual acuity, with a significantly
lower VEGF level in patients who showed greater
improvement of their visual acuity after PPV (r = -
0.3342, p = 0.0135, Figure 2).
Relations between visual acuity, foveal thickness, and 
clinical factors
The following factors were investigated for an influence
on best-corrected visual acuity and the foveal thickness:
gender, age, hypertension, duration of BRVO, retinal pho-
tocoagulation, and the vitreous level of VEGF. As a result,
the vitreous level of VEGF and performance of retinal
photocoagulation were found to be significantly corre-
lated with the improvement of visual acuity and with the
decrease of foveal thickness (p = 0.0282 and p = 0.0026, p
= 0.0286 and p = 0.0419, respectively) (Table 1).
Analysis of the 26 patients who had laser surgery prior
to vitrectomy showed that the vitreous level of vascular
endothelial growth factor was not associated with
improvement of macular edema or improvement of visual
acuity (r = 0.3826, p = 0.0572 and r = - 0.3127, p = 0.1198,
respectively). This may have been because 26 eyes was
too small a sample. There was no significant difference of
the VEGF level between the 26 eyes that received retinal
photocoagulation and the 28 eyes without retinal photo-
coagulation (p = 0.3634).
Analysis of the 25 patients who did not have cataract
surgery revealed that the vitreous level of vascular
endothelial growth factor was not associated with
improvement of macular edema or improvement of visual
acuity (r = 0.2904, p = 0.1568 and r = - 0.1856, p = 0.3633,
respectively), also possibly because of the small sample
size. There were no significant differences of VEGF levels,
improvement of macular edema, or improvement of
visual acuity when we compared the group that did not
undergo cataract surgery with the group that had cataract
surgery (p = 0.5093, p = 0.8731, and p = 0.4946, respec-
tively).
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Discussion
The present study demonstrated that the vitreous level of
VEGF was significantly higher in BRVO patients who
showed less improvement of their best-corrected visual
acuity after PPV (Figure 1). As a result, the VEGF level
had a significant influence on the visual outcome accord-
ing to multivariate analysis. These findings suggest that
measurement of VEGF in the vitreous fluid may be useful
for predicting the visual prognosis after PPV. In contrast
to our findings, Shimura et al.[12] have reported that the
visual prognosis is not correlated with the vitreous level
of VEGF. However, they did not perform retinal photoco-
agulation, while this was done in the present study. Reti-
nal photocoagulation has been shown to induce the
expression of various cytokines, such as interleukin (IL)-
1. β, IL-6, IL-8, and VEGF, [13,14] suggesting that the
effect of photocoagulation on the production of VEGF
may explain the difference between their findings and
ours.
The Branch Vein Occlusion Study was a multicenter
randomized clinical trial that established guidelines for
use of retinal photocoagulation in the treatment of macu-
lar edema. The effectiveness of argon laser photocoagula-
tion was demonstrated, but it was not recommended
within 3 months of the onset of BRVO because spontane-
ous improvement can occur[15]. However, some patients
have poor visual acuity and persistent macular edema
despite photocoagulation. Recently, PPV combined with
posterior vitreous detachment has been reported to
effectively reduce macular edema and improve visual
acuity in BRVO patients[16,17]. Therefore, we performed
vitrectomy more than 3 months after the onset of BRVO
in patients who had clinically detectable diffuse or cystoid
macular edema, or who had persistent macular edema
after photocoagulation. We also performed cataract sur-
gery in 29 patients, because our subjects were relatively
old with an average age of 63.1 years.
Figure 1 Relation between vascular endothelial growth factor (VEGF) ad macular edema. There is a significant positive correlation between the 
vitreous level of VEGF and the percent change of macular edema (r = 0.3666, p = 0.0064).Noma et al. BMC Ophthalmology 2010, 10:11
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The macula is important for detailed vision, especially
the fovea that consists entirely of cones[18]. In humans,
histological studies have shown that macular edema is
associated with swelling of the Müller cells, especially in
the outer plexiform layer of the neurosensory retina [19-
21]. Accordingly, macular edema may affect retinal func-
tion and lead to visual impairment in BRVO patients.
The present study demonstrated that a higher VEGF
level in the vitreous fluid at the time of surgery was signif-
icantly associated with more marked improvement of
macular edema after PPV, which was in agreement with
our findings in a previous study of PPV for BRVO[7]. The
vitreous level of VEGF was also significantly correlated
with the improvement of BCVA and the decrease of
foveal thickness. Intravitreal injection of VEGF has been
reported to cause retinal edema, dilated and tortuous ves-
sels, and capillary closure in adult primates, [22] while
treatment with bevacizumab (a monoclonal antibody tar-
geting VEGF) or ranibizumab (an Fab fragment that
binds and neutralizes all isoforms of VEGF-A) improves
macular edema in patients with BRVO [23-25]. There-
fore, reduction of the intraocular VEGF level may be one
of the mechanisms by which PPV improves macular
edema in BRVO patients. In agreement with this hypoth-
esis, we previously found that the vitreous level of VEGF
was lower at the time of repeat vitrectomy in patients
with macular edema due to retinal vein occlusion[26].
Interestingly, the improvement of visual acuity and the
improvement of macular edema did not occur in parallel.
Although the retinal thickness at the central fovea has
been reported to influence visual acuity, [27,28] we found
that acuity sometimes showed little improvement even if
macular edema resolved. This may have been because 1)
improvement of visual acuity required longer than the 6-
month follow-up period of this study or 2) improvement
of vision failed to occur after edema resolved because of
permanent photoreceptor cell damage due to macular
ischemia in patients with high VEGF levels. Foveal bleed-
ing could also influence the visual prognosis. Accord-
ingly, a larger prospective and randomized study is
needed to clarify the relation between visual acuity and
macular edema in patients with BRVO.
Figure 2 Relation between vascular endothelial growth factor (VEGF) and visual acuity. There is a significant negative correlation between the 
vitreous level of VEGF and the improvement of best-corrected visual acuity (BCVA) (r = -0.3342, p = 0.0135).Noma et al. BMC Ophthalmology 2010, 10:11
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In the present study, multivariate analysis showed that
the vitreous VEGF level and retinal photocoagulation
were significantly correlated with improvement of visual
acuity and with the decrease of foveal thickness. Aiello et
al.[9] previously reported that the vitreous level of VEGF
was reduced by retinal photocoagulation, and our find-
ings would suggest that the decrease of VEGF due to reti-
nal photocoagulation results in improvement of BCVA
and a decrease of foveal thickness. However, the relations
between retinal photocoagulation, the vitreous level of
VEGF, improvement of visual acuity, and improvement of
macular edema in patients with BRVO need to be investi-
gated further.
The present study had several limitations. One major
problem was the performance of laser photocoagulation
prior to surgery. For the following reasons, we performed
a combined analysis of the groups with (n = 26) and with-
out (n = 28) laser photocoagulation. The first reason is
that there was no significant difference of the VEGF level
between the 26 eyes that received retinal photocoagula-
tion and the 28 eyes without it (data not shown, p =
0.6755). Secondly, laser photocoagulation increases the
expression of various cytokines, including VEGF, by cul-
tured human retinal pigment epithelial (RPE) cells, but
upregulation of VEGF occurs from 6 hours after photoco-
agulation and there is a return to the basal level by 72
hours[29]. In contrast, Itaya et al.[30] found the maxi-
mum VEGF level on day 3 in vivo, coinciding with the
peak of macrophage infiltration. They suggested that the
difference from in vitro data arose because infiltrating
macrophages contributed more to upregulation of VEGF
than RPE cells or because secretion of VEGF was induced
by the interaction of macrophages with RPE cells. Fur-
thermore, changes of retinal VEGF mRNA expression
after laser photocoagulation were confined to RPE cells in
miniature pigs, with reduced mRNA expression immedi-
ately after photocoagulation and a return to normal by 42
days[31]. These results suggest that any increase of VEGF
expression in the retina after photocoagulation is tran-
sient, and that the VEGF level decreases again relatively
fast and then becomes stable. Because the average inter-
val was 2.3 ± 1.5 months from laser photocoagulation to
vitrectomy, photocoagulation is unlikely to have influ-
enced VEGF levels. Another limitation of this study was
the performance of cataract extraction at the time of vit-
rectomy. However, there were no significant differences
of VEGF levels, improvement of macular edema, or
improvement of visual acuity between the patients under-
going cataract surgery and those who did not. Multiple
r e g r e s s i o n  a n a l y s i s  d e m o n s t r a t e d  t h a t  c a t a r a c t  s u r g e r y
was not correlated with the improvement of macular
edema or the improvement of visual acuity. Therefore,
cataract surgery did not influence our results. Further
investigations will be needed to clarify the relation among
the vitreous level of VEGF, improvement of macular
edema, and improvement of visual acuity, as well as the
possible effects of laser photocoagulation and cataract
surgery.
Conclusions
The present study showed that the vitreous level of VEGF
was significantly higher in BRVO patients with less
improvement of best-corrected visual acuity after PPV. In
contrast, patients with high vitreous VEGF levels dis-
Table 1: Results of multivariate analysis of factors influencing the improvement of best-corrected visual acuity (BCVA) and 
the decrease of foveal thickness.
Improvement of BCVA
(log MAR)
Decrease of foveal thickness
Variable Standard partial
regression 
coefficient
P value Standard partial
regression 
coefficient
P value
Age (years) 0.166 0.1972 0.004 0.9749
Gender 0.114 0.3722 0.226 0.0803
Hypertension 0.098 0.4577 0.081 0.5345
Duration of BRVO 
(months)
-0.195 0.1497 -0.108 0.4190
Cataract surgery 0.039 0.7600 -0.068 0.5944
Retinal 
photocoagulation
0.307 0.0253 -0.273 0.0449
Vitreous VEGF level 
(pg/ml)
0.296 0.0270 0.422 0.0020
log MAR = logarithm of the minimum angle of resolution; BRVO = branch retinal vein occlusion; VEGF = vascular endothelial growth factorNoma et al. BMC Ophthalmology 2010, 10:11
http://www.biomedcentral.com/1471-2415/10/11
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played greater improvement of macular edema than
those with low VEGF levels. These results suggest that
VEGF in the vitreous fluid might influence both the
visual prognosis and the response of macular edema to
vitrectomy in patients with BRVO.
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